The Case for the Use of Patient and Caregiver Perception of Change Assessments in Rare Disease Clinical Trials: A Methodologic Overview
- PMID: 30879250
- PMCID: PMC6824378
- DOI: 10.1007/s12325-019-00920-x
The Case for the Use of Patient and Caregiver Perception of Change Assessments in Rare Disease Clinical Trials: A Methodologic Overview
Abstract
Introduction: The traditional model of evaluating treatments based primarily on primary outcome measures has stumbled in its application to rare disease. Rare disease clinical trials face the methodological challenges of small, heterogeneous patient populations and relatively few validated, disease-specific outcome measures. Incorporating qualitative research into rare disease clinical trials may help sponsors, regulators, payers, and prescribers to better understand the real-world and patient-specific impact of a potential therapy. This paper provides a methodologic overview of the use of Patient and Caregiver Perception of Change (PPC and CPC) Assessments utilizing patient and caregiver video interviews to complement the data captured by traditional endpoints in rare disease clinical trials.
Methods: Incorporating qualitative patient and caregiver video interviews into clinical trials allows for the rigorous capture of patient experiences and caregiver observations. Interview guides informed by input from key stakeholders provide the opportunity to solicit structured feedback on experiences before, during, and after the clinical trial. Patients and caregivers can complete their video interviews in a study mobile application, and interview transcripts are analyzed by independent coders. Themes are summarized by the treatment group and individual patient, which adds context to the clinical outcome measures of how patients feel and function, as well as elucidates the degree of change that is meaningful to patients and caregivers. The qualitative results can be compared to the data captured in clinical trials to assess data concordance.
Conclusion: Capturing patient experience data with sufficient rigor allows it to contribute to the body of evidence utilized in regulatory, payer, and prescriber decision-making. Adding PPC and CPC Assessments to rare disease clinical trials offers an innovative and powerful way to tap into the unique insights of patients and their families to develop a fuller picture of the patient experience in the clinical trial.
Funding: Stealth BioTherapeutics Inc.
Keywords: Clinical outcome assessment; Genetic disease; Mixed methods research; Observer-reported outcomes; Patient experience data; Patient focused drug development; Patient-reported outcomes; Qualitative research; Rare diseases.
Conflict of interest statement
Tracy E. Wall works for Stealth BioTherapeutics Inc., the funder of this research. Marielle Goyette Contesse works for Casimir, a company that received payment from Stealth BioTherapeutics Inc., for work on this manuscript. Mindy G. Leffler works for Casimir, a company that received payment from Stealth BioTherapeutics Inc., for work on this manuscript. James E. Valentine works for Hyman, Phelps & McNamara, P.C., a law firm that represents Stealth BioTherapeutics Inc., including through the time when work was performed on this manuscript.
Figures
Similar articles
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Bringing Patient and Caregivers Voices to the Clinical Trial Chorus: A Report From the BMT CTN Patient and Caregiver Advocacy Task Force.Transplant Cell Ther. 2023 Jan;29(1):5-9. doi: 10.1016/j.jtct.2022.10.016. Epub 2022 Oct 23. Transplant Cell Ther. 2023. PMID: 36283516 Free PMC article.
-
Unexpected challenges faced by caregivers of children with neurogenic bladder: A qualitative study.J Pediatr Urol. 2022 Aug;18(4):502.e1-502.e9. doi: 10.1016/j.jpurol.2022.06.005. Epub 2022 Jun 16. J Pediatr Urol. 2022. PMID: 35810140
-
[Caregiver burden in relatives of persons with schizophrenia: an overview of measure instruments].Encephale. 2003 Mar-Apr;29(2):137-47. Encephale. 2003. PMID: 14567165 Review. French.
-
Capturing Real-World Rare Disease Patient Journeys: Are Current Methodologies Sufficient for Informed Healthcare Decisions?J Eval Clin Pract. 2025 Feb;31(1):e70010. doi: 10.1111/jep.70010. J Eval Clin Pract. 2025. PMID: 39960234 Free PMC article.
Cited by
-
Patient Experience Data for Medical Product Development: Opportunity Beyond Obligation.Patient. 2022 Mar;15(2):147-149. doi: 10.1007/s40271-021-00570-8. Epub 2022 Jan 26. Patient. 2022. PMID: 35083736 No abstract available.
-
U.S. Food and Drug Administration's Patient-Focused Drug Development Initiative: Experience with Integration of Patient-Experience Data in a New Drug Application for Esketamine Nasal Spray Plus a Newly Initiated Oral Antidepressant for Treatment-Resistant Depression.Ther Innov Regul Sci. 2022 Jan;56(1):38-46. doi: 10.1007/s43441-021-00340-6. Epub 2021 Oct 8. Ther Innov Regul Sci. 2022. PMID: 34623613 Free PMC article.
-
A systematic review of moral reasons on orphan drug reimbursement.Orphanet J Rare Dis. 2021 Jun 30;16(1):292. doi: 10.1186/s13023-021-01925-y. Orphanet J Rare Dis. 2021. PMID: 34193232 Free PMC article.
-
Establishing a core outcome set for creatine transporter deficiency and guanidinoacetate methyltransferase deficiency.Orphanet J Rare Dis. 2025 Aug 7;20(1):408. doi: 10.1186/s13023-025-03900-3. Orphanet J Rare Dis. 2025. PMID: 40775643 Free PMC article.
-
RD-LIVES: A Living Evidence Synthesis System for Rare Disease Treatment Efficacy and Safety.AMIA Jt Summits Transl Sci Proc. 2025 Jun 10;2025:607-613. eCollection 2025. AMIA Jt Summits Transl Sci Proc. 2025. PMID: 40502246 Free PMC article.
References
-
- U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Rare diseases: common issues in drug development—guidance for industry. Silver Spring, MD; 2019.
-
- NIH. FAQs About Rare Diseases | Genetic and Rare Diseases Information Center (GARD)—an NCATS Program [Internet]. 2017. https://rarediseases.info.nih.gov/diseases/pages/31/faqs-about-rare-dise.... Accessed 19 Sept 2018.
-
- RARE Diseases: Facts and statistics [Internet]. Global Genes. 2012. http://globalgenes.org/rare-diseases-facts-statistics/. Accessed 19 Sept 2018.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous